Int. J. Mol. Sci. 2014, 15(5), 8713-8742; https://doi.org/10.3390/ijms15058713
Role of Mitochondria in Nonalcoholic Fatty Liver Disease
Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Missouri, Columbia, MO 65212, USA
*
Author to whom correspondence should be addressed.
Received: 4 March 2014 / Revised: 4 May 2014 / Accepted: 7 May 2014 / Published: 15 May 2014
(This article belongs to the Collection Molecular Mechanisms of Human Liver Diseases)
Abstract
Nonalcoholic fatty liver disease (NAFLD) affects about 30% of the general population in the United States and includes a spectrum of disease that includes simple steatosis, non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis. Significant insight has been gained into our understanding of the pathogenesis of NALFD; however the key metabolic aberrations underlying lipid accumulation in hepatocytes and the progression of NAFLD remain to be elucidated. Accumulating and emerging evidence indicate that hepatic mitochondria play a critical role in the development and pathogenesis of steatosis and NAFLD. Here, we review studies that document a link between the pathogenesis of NAFLD and hepatic mitochondrial dysfunction with particular focus on new insights into the role of impaired fatty acid oxidation, the transcription factor peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α), and sirtuins in development and progression of NAFLD. View Full-TextKeywords:
NAFLD; NASH; mitochondria; liver; steatosis; fatty acid oxidation; PGC-1α; sirtuin-1 (SIRT1); sirtuin-3 (SIRT3)
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
Share & Cite This Article
MDPI and ACS Style
Nassir, F.; Ibdah, J.A. Role of Mitochondria in Nonalcoholic Fatty Liver Disease. Int. J. Mol. Sci. 2014, 15, 8713-8742.
Related Articles
Article Metrics
Comments
[Return to top]
Int. J. Mol. Sci.
EISSN 1422-0067
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert